NASDAQ : VKTX
Viking Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 26.86 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 3.43B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 62.41M | 48.39M | 49.28M | 37.02M | 16.12M | 10.70M |
| Research & Development | 586.17M | 344.95M | 101.64M | 63.81M | 54.23M | 44.98M |
| Operating Expenses | 648.57M | 393.34M | 150.92M | 100.83M | 70.36M | 55.68M |
| Operating Income | -648.57M | -393.34M | -150.92M | -100.83M | -70.36M | -55.68M |
| Interest Expense | -88.00K | -56.00K | -94.00K | -88.00K | -59.00K | -18.00K |
| Interest & Investment Income | 21.39M | 33.70M | 40.94M | 15.02M | 1.59M | 703.00K |
| Currency Exchange Gain (Loss) | 7.00K | |||||
| EBT Excluding Unusual Items | -627.27M | -359.69M | -110.08M | -85.89M | -68.83M | -54.99M |
| Gain (Loss) on Sale of Investments | 71.00K | 55.00K | 112.00K | -42.00K | ||
| Pretax Income | -627.20M | -359.64M | -109.96M | -85.89M | -68.87M | -54.99M |
| Net Income | -627.20M | -359.64M | -109.96M | -85.89M | -68.87M | -54.99M |
| Net Income to Common | -627.20M | -359.64M | -109.96M | -85.89M | -68.87M | -54.99M |
| Shares Outstanding (Basic) | 115.98M | 112.67M | 109.04M | 94.35M | 76.83M | 77.20M |
| Shares Outstanding (Diluted) | 115.98M | 112.67M | 109.04M | 94.35M | 76.83M | 77.20M |
| EPS (Basic) | -5.41 | -3.19 | -1.01 | -0.91 | -0.90 | -0.71 |
| EPS (Diluted) | -5.41 | -3.19 | -1.01 | -0.91 | -0.90 | -0.71 |
| EBIT | -648.57M | -393.34M | -150.92M | -100.83M | -70.36M | -55.68M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 677.61M | 165.81M | 26.68M | 55.52M | 36.63M | 26.37M |
| Short-Term Investments | 282.20M | 539.93M | 875.94M | 306.56M | 118.85M | 175.73M |
| Cash & Short-Term Investments | 959.81M | 705.74M | 902.61M | 362.08M | 155.49M | 202.10M |
| Prepaid Expenses | 3.18M | 1.81M | 1.13M | 2.52M | 3.41M | 619.00K |
| Other Current Assets | 10.01M | 8.05M | 3.48M | 2.62M | 8.14M | 7.81M |
| Total Current Assets | 973.00M | 715.60M | 907.22M | 367.23M | 167.04M | 210.53M |
| Property, Plant & Equipment | 3.85M | 85.00K | 1.00M | 1.13M | 1.42M | 25.00K |
| Long-Term Deferred Charges | 56.00K | 106.00K | 38.00K | 76.00K | ||
| Other Long-Term Assets | 315.00K | 46.00K | 46.00K | 33.00K | 33.00K | 33.00K |
| Total Assets | 977.17M | 715.73M | 908.32M | 368.49M | 168.53M | 210.66M |
| Accounts Payable | 82.13M | 53.25M | 9.81M | 7.51M | 8.53M | 1.44M |
| Accrued Expenses | 51.74M | 23.28M | 17.11M | 11.30M | 13.11M | 7.30M |
| Current Portion of Leases | 24.00K | 137.00K | 489.00K | 324.00K | 304.00K | 29.00K |
| Total Current Liabilities | 133.90M | 76.67M | 27.41M | 19.14M | 21.95M | 8.78M |
| Long-Term Debt | 250.66M | |||||
| Long-Term Leases | 4.01M | 630.00K | 936.00K | 1.26M | ||
| Total Liabilities | 388.57M | 76.67M | 28.04M | 20.07M | 23.21M | 8.78M |
| Common Stock | 1.00K | 1.00K | 1.00K | 1.00K | 1.00K | 1.00K |
| Additional Paid-In Capital | 1.91B | 1.49B | 1.37B | 733.55M | 445.27M | 425.61M |
| Retained Earnings | -1.32B | -847.55M | -487.91M | -377.94M | -292.05M | -223.18M |
| Treasury Stock | -6.79M | -6.79M | ||||
| Comprehensive Income & Other | -1.70M | 378.00K | -788.00K | -389.00K | -1.10M | -549.00K |
| Shareholders' Equity | 588.60M | 639.06M | 880.28M | 348.42M | 145.32M | 201.88M |
| Total Liabilities & Equity | 977.17M | 715.73M | 908.32M | 368.49M | 168.53M | 210.66M |
| Total Debt | 254.69M | 137.00K | 1.12M | 1.26M | 1.56M | 29.00K |
| Net Cash (Debt) | 705.12M | 705.60M | 901.49M | 360.82M | 153.92M | 202.07M |
| Net Cash Per Share | 6.08 | 6.26 | 8.27 | 3.82 | 2.00 | 2.62 |
| Filing Date Shares Outstanding | 127.52M | 115.55M | 112.25M | 100.49M | 78.42M | 78.36M |
| Total Common Shares Outstanding | 127.52M | 114.79M | 111.57M | 100.11M | 78.26M | 78.25M |
| Working Capital | 839.10M | 638.93M | 879.80M | 348.09M | 145.09M | 201.75M |
| Book Value Per Share | 4.62 | 5.57 | 7.89 | 3.48 | 1.86 | 2.58 |
| Tangible Book Value | 588.60M | 639.06M | 880.28M | 348.42M | 145.32M | 201.88M |
| Tangible Book Value Per Share | 4.62 | 5.57 | 7.89 | 3.48 | 1.86 | 2.58 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -627.20M | -359.64M | -109.96M | -85.89M | -68.87M | -54.99M |
| Depreciation & Amortization | 494.00K | 431.00K | 346.00K | 292.00K | 291.00K | 296.00K |
| Other Amortization | 56.00K | 94.00K | 88.00K | 59.00K | 18.00K | |
| Loss (Gain) From Sale of Investments | -4.78M | -9.34M | -17.38M | -8.20M | 1.22M | 3.91M |
| Stock-Based Compensation | 47.95M | 40.82M | 29.71M | 16.75M | 8.67M | 6.10M |
| Other Operating Activities | 187.00K | 10.00K | 38.00K | 43.00K | 41.00K | 11.00K |
| Change in Accounts Payable | 77.72M | 43.44M | 2.30M | -1.02M | 7.08M | -2.54M |
| Change in Other Net Operating Assets | 42.99M | 5.54M | 7.06M | 4.57M | 3.10M | -383.00K |
| Operating Cash Flow | -462.63M | -278.69M | -87.79M | -73.38M | -48.40M | -47.59M |
| Investment in Securities | 331.75M | 341.39M | -553.37M | -179.09M | 54.75M | 37.96M |
| Investing Cash Flow | 331.75M | 341.39M | -553.37M | -179.09M | 54.75M | 37.96M |
| Net Debt Issued (Repaid) | 251.00M | |||||
| Issuance of Common Stock | 457.31M | 76.44M | 654.57M | 278.50M | 12.51M | 7.63M |
| Repurchase of Common Stock | -42.10M | -7.12M | -8.33M | -707.00K | ||
| Other Financing Activities | -22.00K | -46.00K | ||||
| Financing Cash Flow | 708.32M | 76.44M | 612.46M | 271.38M | 4.16M | 6.88M |
| Foreign Exchange Rate Adjustments | -1.00K | -8.00K | -148.00K | -30.00K | -258.00K | |
| Net Cash Flow | 577.43M | 139.13M | -28.84M | 18.88M | 10.26M | -2.75M |
| Levered Free Cash Flow | -237.78M | -160.22M | -55.58M | -42.36M | -25.22M | -32.16M |
| Unlevered Free Cash Flow | -237.72M | -160.24M | -55.61M | -42.40M | -25.24M | -32.16M |
| Change in Working Capital | 120.71M | 48.98M | 9.36M | 3.55M | 10.19M | -2.93M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 3.42B | 3.98B | 4.48B | 1.86B | 720.87M | 359.88M |
| Enterprise Value | 2.72B | 3.26B | 3.55B | 1.49B | 567.48M | 143.86M |
| Last Close Price | 27.28 | 35.18 | 40.24 | 18.61 | 9.40 | 4.60 |
| PB Ratio | 5.91 | 6.22 | 5.09 | 5.34 | 4.96 | 1.78 |
| P/TBV Ratio | 5.81 | 6.22 | 5.09 | 5.34 | 4.96 | 1.78 |
| Debt / Equity Ratio | 0.43 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Net Debt / Equity Ratio | -1.20 | -1.10 | -1.02 | -1.04 | -1.06 | -1.00 |
| Quick Ratio | 7.17 | 9.21 | 32.93 | 18.92 | 7.08 | 23.02 |
| Current Ratio | 7.27 | 9.33 | 33.09 | 19.19 | 7.61 | 23.98 |
| Return on Equity (ROE) | -96.37% | -47.34% | -17.90% | -34.79% | -39.67% | -24.65% |
| Return on Assets (ROA) | -47.23% | -30.28% | -14.77% | -23.47% | -23.19% | -14.90% |
| Return on Capital Employed (ROCE) | -76.90% | -61.50% | -17.10% | -28.90% | -48.00% | -27.60% |
| Earnings Yield | -20.16% | -9.04% | -2.45% | -4.61% | -9.55% | -15.28% |
| Buyback Yield / Dilution | -3.55% | -3.33% | -15.57% | -22.79% | 0.47% | -6.34% |